Alexander W Wyatt

List of Publications by Year
in descending order

73 papers	5,784 citations	126858 33 h-index	85498 71 g-index
75 all docs	75 docs citations	75 times ranked	7294 citing authors

#	Article	IF	Citations
1	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell, 2018, 174, 758-769.e9.	13.5	459
2	Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2015, 21, 2315-2324.	3.2	407
3	Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. Cancer Discovery, 2018, 8, 444-457.	7.7	376
4	High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development. Cancer Research, 2014, 74, 1272-1283.	0.4	304
5	Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. JAMA Oncology, 2016, 2, 1598.	3.4	290
6	Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	288
7	The Master Neural Transcription Factor BRN2 Is an Androgen Receptorâ€“Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. Cancer Discovery, 2017, 7, 54-71.	7.7	285
8	Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncology, The, 2019, 20, 1730-1739.	5.1	227
9	Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discovery, 2017, 7, 999-1005.	7.7	223
10	The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. Cell Reports, 2015, 12, 922-936.	2.9	216
11	The DNA methylation landscape of advanced prostate cancer. Nature Genetics, 2020, 52, 778-789.	9.4	198
12	Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repairâ€“deficient Prostate Cancer. European Urology, 2017, 72, 34-42.	0.9	179
13	Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biology, 2016, 17, 10.	3.8	165
14	From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. Journal of Pathology, 2012, 227, 286-297.	2.1	161
15	Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. European Urology, 2019, 75, 667-675.	0.9	131
16	Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. Clinical Cancer Research, 2017, 23, 6487-6497.	3.2	121
17	Targeting the adaptive molecular landscape of castrationâ€resistant prostate cancer. EMBO Molecular Medicine, 2015, 7, 878-894.	3.3	110
18	Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. European Urology, 2019, 75, 707-711.	0.9	89

#	Article	IF	Citations
19	Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy. Scientific Reports, 2017, 7, 42713.	1.6	85
20	Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nature Communications, 2021, 12, 184.	5.8	85
21	Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. Genome Biology, 2014, 15, 426.	3.8	71
22	Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. Clinical Cancer Research, 2017, 23, 6802-6811.	3.2	69
23	nFuse: Discovery of complex genomic rearrangements in cancer using high-throughput sequencing. Genome Research, 2012, 22, 2250-2261.	2.4	67
24	Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. European Urology, 2020, 77, 333-341.	0.9	65
25	Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. Journal of Pathology, 2012, 227, 53-61.	2.1	63
26	Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer. Clinical Cancer Research, 2020, 26, 1114-1125.	3.2	57
27	BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression. Clinical Cancer Research, 2021, 27, 1650-1662.	3.2	52
28	Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer. European Urology, 2021, 79, 762-771.	0.9	47
29	Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. European Urology, 2020, 78, 834-844.	0.9	47
30	Polyâ€gene fusion transcripts and chromothripsis in prostate cancer. Genes Chromosomes and Cancer, 2012, 51, 1144-1153.	1.5	46
31	Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. Clinical Cancer Research, 2021, 27, 4610-4623.	3.2	41
32	The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing. Asian Journal of Andrology, 2013, 15, 301-308.	0.8	39
33	Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. Journal of Clinical Oncology, 2021, 39, 2926-2937.	0.8	36
34	DNA repair defects in prostate cancer: impact for screening, prognostication and treatment. BJU International, 2019, 123, 769-776.	1.3	35
35	Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 826-836.	0.8	33
36	Technical and biological constraints on ctDNA-based genotyping. Trends in Cancer, 2021, 7, 995-1009.	3.8	33

#	Article	IF	Citations
37	Biallelic tumour suppressor loss and DNA repair defects in de novo smallâ€cell prostate carcinoma. Journal of Pathology, 2018, 246, 244-253.	2.1	32
38	Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, 322-331.e2.	0.9	30
39	Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 287-294.	0.8	28
40	Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer. JCO Precision Oncology, 2019, 3, 1-9.	1.5	26
41	Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review. European Urology Oncology, 2021, 4, 914-923.	2.6	23
42	Frequent mutation of the FOXA1 untranslated region in prostate cancer. Communications Biology, 2018, 1, 122.	2.0	21
43	Isolation and genome sequencing of individual circulating tumor cells using hydrogel encapsulation and laser capture microdissection. Lab on A Chip, 2018, 18, 1736-1749.	3.1	21
44	Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. Journal of Pathology: Clinical Research, 2021, 7, 311-325.	1.3	19
45	Biomarkers for Programmed Deathâ€1 Inhibition in Prostate Cancer. Oncologist, 2019, 24, 444-448.	1.9	18
46	Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer. Cancer Cytopathology, 2019, 127, 578-585.	1.4	16
47	In Brief: Chromothripsis and cancer. Journal of Pathology, 2013, 231, 1-3.	2.1	15
48	Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer. Clinical Genitourinary Cancer, 2016, 14, e233-e236.	0.9	15
49	Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. JCO Precision Oncology, 2019, 3, 1-13.	1.5	15
50	Differential treatment outcomes in BRCA1/2â€, CDK12â€, and ATMâ€mutated metastatic castrationâ€resistant prostate cancer. Cancer, 2021, 127, 1965-1973.	2.0	15
51	Predicting therapy response and resistance in metastatic prostate cancer with circulating tumor DNA. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 380-384.	0.8	13
52	Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 573.e19-573.e29.	0.8	13
53	Clinical implications of genomic alterations in metastatic prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 310-322.	2.0	12
54	Clinical utility of emerging liquid biomarkers in advanced prostate cancer. Cancer Genetics, 2018, 228-229, 151-158.	0.2	11

#	Article	IF	Citations
55	Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. Urology, 2021, 155, 165-171.	0.5	11
56	Concurrent germline and somatic pathogenic BAP1 variants in a patient with metastatic bladder cancer. Npj Genomic Medicine, 2020, 5, 12.	1.7	9
57	A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines. PLoS ONE, 2014, 9, e103050.	1.1	7
58	Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer. JCO Precision Oncology, 2022, 6, e2100543.	1.5	7
59	Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease. Clinical Cancer Research, 2021, 27, 4539-4548.	3.2	6
60	Somatic Features of Response and Relapse in Nonâ€“muscle-invasive Bladder Cancer Treated with Bacillus Calmette-GuÃ©rin Immunotherapy. European Urology Oncology, 2022, 5, 677-686.	2.6	6
61	Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer. Prostate, 2022, 82, .	1.2	6
62	Building confidence in circulating tumour DNA assays for metastatic castration-resistant prostate cancer. Nature Reviews Urology, 2021, 18, 255-256.	1.9	4
63	Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay. NAR Cancer, 2022, 4, .	1.6	4
64	Circulating Tumour DNA as a Biomarker Source in Metastatic Prostate Cancer. SociÃ©tÃ© Internationale D'urologie Journal, 2020, 1, 39-48.	0.2	3
65	Genomic biomarkers to guide precision radiotherapy in prostate cancer. Prostate, 2022, 82, .	1.2	3
66	Olaparib for the treatment of metastatic prostate cancer. Future Oncology, 2021, 17, 2413-2429.	1.1	2
67	Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context. Canadian Urological Association Journal, 2021, 16, .	0.3	2
68	Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2017, 15, e145-e150.	0.9	1
69	Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 1588.	1.7	1
70	Reply to Rodolfo Montironi, Liang Cheng, Marina Scarpelli, Alessia Cimadamore, Francesco Montorsi, and Antonio Lopez-Beltran's Letter to the Editor re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667â€“75: How Does Circulating DNA Reach the Blood Stream?. European Urology, 2019, 76, e73-e74.	0.9	0
71	B2B: Prostate Cancer. SociÃ©tÃ© Internationale D'urologie Journal, 2021, 2, S30-S50.	0.2	0
72	Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors. Urology Case Reports, 2021, 39, 101762.	0.1	0

#	Article	IF	Citations
73	Quality and Quantity: Evaluating Tumor Biology Alongside Novel Imaging on Diagnosis of Metastatic Hormone-sensitive Prostate Cancer. European Urology, 2022, 81, 437-439.	0.9	0